<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24579" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Lymphohistiocytosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Konkol</surname>
            <given-names>Sam</given-names>
          </name>
          <aff>University of Virginia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rai</surname>
            <given-names>Maitreyee</given-names>
          </name>
          <aff>Crozer Chester Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sam Konkol declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maitreyee Rai declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>27</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24579.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening, hyper-inflammatory disorder affecting both newborns and adults alike. The disease is characterized by dysregulated immune activity resulting in malignant inflammation and multi-organ failure. This activity reviews the evaluation and treatment of HLH and highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of hemophagocytic lymphohistiocytosis.</p></list-item><list-item><p>Review the laboratory findings consistent with a diagnosis of hemophagocytic lymphohistiocytosis.</p></list-item><list-item><p>Outline the management options available for hemophagocytic lymphohistiocytosis.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance the management of hemophagocytic lymphohistiocytosis and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24579&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24579">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24579.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hemophagocytic lymphohistiocytosis (HLH) is a devastating, hyper-inflammatory condition that results in multi-organ failure and death. The systemic inflammation that characterizes the disease is the result of inappropriate and dysregulated activation of natural killer (NK) cells, CD8+ cytotoxic T-cells, and macrophages. The disease is classified as either primary (the result of inherited genetic mutations) or secondary (an inappropriate host response to infection, malignancy, or autoimmune disease). Patients with primary disease present early in childhood, whereas those with secondary disease present as adults with an associated acute illness, most commonly sepsis or a hematologic malignancy. Treatment is focused on immunosuppression coupled with cytotoxic chemotherapy, without which large proportions of patients inevitably die.<xref ref-type="bibr" rid="article-24579.r1">[1]</xref><xref ref-type="bibr" rid="article-24579.r2">[2]</xref><xref ref-type="bibr" rid="article-24579.r3">[3]</xref><xref ref-type="bibr" rid="article-24579.r4">[4]</xref></p>
      </sec>
      <sec id="article-24579.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>HLH presents as two distinct clinical entities: primary or secondary</p>
        <list list-type="bullet">
          <list-item>
            <p>Primary HLH presents in early childhood as the result of genetic mutations that impair the interaction between NK cells, CD8+ cytotoxic T-cells, and antigen-presenting cells. As a result, these ineffective and dysregulated cells increase their production of pro-inflammatory cytokines leading to systemic activation of macrophages and the subsequent cellular destruction that ensues. Primary HLH is further subdivided by the hereditability of the genetic mutations involved (X-linked versus recessive versus dominant) or the clinical syndromes with which it can be associated (i.e., Chediak Higashi syndrome, Griscelli syndrome, X-linked lymphoproliferative disorder, etc.). Forms without an associated genetic syndrome are typically referred to as familial HLH.<xref ref-type="bibr" rid="article-24579.r2">[2]</xref><xref ref-type="bibr" rid="article-24579.r5">[5]</xref><xref ref-type="bibr" rid="article-24579.r6">[6]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Secondary HLH presents in adults (mean age of approximately 50) in response to an acute illness trigger rather than an underlying genetic mutation. The most common triggers involved in secondary HLH include infection, malignancy, and autoimmune disorders. Classically, HLH, which occurs in the context of an autoimmune disorder, is referred to as macrophage activation syndrome (MAS). This is more a historical relic than an indication of a separate disease process. Interestingly, around 14% of adult patients have allelic abnormalities in primary HLH genes. The significance of these allelic polymorphisms is not fully understood; however, it is hypothesized that they serve as predisposing factors in the face of specific triggers.<xref ref-type="bibr" rid="article-24579.r1">[1]</xref><xref ref-type="bibr" rid="article-24579.r6">[6]</xref><xref ref-type="bibr" rid="article-24579.r7">[7]</xref><xref ref-type="bibr" rid="article-24579.r8">[8]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24579.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Accurate estimates of the prevalence and distribution of HLH within the population are difficult to obtain due to various factors, the most apparent of which is imprecise diagnostic criteria and the presence of multiple confounding medical illnesses at the time of diagnosis. The most comprehensive data with regards to primary HLH comes from a Swedish national registry that collected data from 1987-2006 and demonstrated a yearly incidence of roughly 1.5 per million.<xref ref-type="bibr" rid="article-24579.r9">[9]</xref> For children admitted to the intensive care unit (ICU), a retrospective review of 30,000 pediatric admissions at Texas Children&#x02019;s Hospital estimated the incidence as high as 1 in 3,000.<xref ref-type="bibr" rid="article-24579.r10">[10]</xref> &#x000a0;&#x000a0;</p>
        <p>In adults with secondary HLH, accurate estimates are even more difficult. Not only is the presentation often indistinguishable from the underlying trigger (sepsis, uncontrolled malignancy, autoimmune flare), but laboratory investigations to confirm HLH are infrequently undertaken. That being said, some estimates place it at 1 in 2000 for adult critical care admissions.<xref ref-type="bibr" rid="article-24579.r11">[11]</xref> Suspicion and institutional culture greatly affect the diagnostic workup and, therefore, the recorded incidence of the disease.<xref ref-type="bibr" rid="article-24579.r6">[6]</xref>&#x000a0;</p>
        <p>No clear racial or ethnic predilection has been observed in the literature; rather, these categories tend to distribute in a fashion that approximates the surrounding geographic location of the study. <xref ref-type="bibr" rid="article-24579.r10">[10]</xref> In the two largest epidemiologic studies in children, the gender distribution was approximately 1&#x000a0;to 1.<xref ref-type="bibr" rid="article-24579.r9">[9]</xref><xref ref-type="bibr" rid="article-24579.r12">[12]</xref>&#x000a0;However, in adults, there may be a slightly increased ratio of HLH in males compared to females of slightly less than 2&#x000a0;to 1.<xref ref-type="bibr" rid="article-24579.r4">[4]</xref><xref ref-type="bibr" rid="article-24579.r11">[11]</xref></p>
      </sec>
      <sec id="article-24579.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>HLH is characterized by a dysregulated innate immune system, specifically NK cells and CD 8+ cytotoxic T-cells. In a healthy immune system, NK cells and CD 8+ cytotoxic T-cells produce two cytolytic enzymes: perforin and granzyme. These proteins are packaged into granules that are discharged into the immunologic synapse between the effector and target cell. Perforin forms destabilizing pores in the target cell's membrane allowing for the entrance of the strongly proteolytic granzyme as well as osmotic shifts, which result in target cell degradation. In patients with HLH, this process is disrupted through specific genetic mutations or acquired through some highly immunogenic stimulus (a viral infected or malignant cell). The ineffective interaction between NK cells, CD 8+ cytotoxic T-cells, and their targets leads to a vicious cycle of inflammation. More and more cytotoxic cells are recruited but remain unable to rid the body of the pathologic antigen, and a massive increase in circulating cytokines occurs. This hypercytokinemia leads to widespread activation of macrophages and the resultant hemophagocytosis and excessive, organ-damaging inflammation, which characterizes the disease.<xref ref-type="bibr" rid="article-24579.r1">[1]</xref>&#x000a0;</p>
        <p>The first genetic mutations identified in primary or familial HLH were located in the PRF1 gene, which encodes for perforin.<xref ref-type="bibr" rid="article-24579.r13">[13]</xref> Subsequently, several genetic mutations and associated syndromes have been identified with varying patterns of inheritability (recessive, autosomal, or X-linked). Although secondary HLH is classically understood as a purely acquired disorder, a large institutional series found genetic polymorphisms in primary HLH genes in 14% of adults, including in patients more than 70 years old.<xref ref-type="bibr" rid="article-24579.r14">[14]</xref>&#x000a0;&#x000a0;</p>
        <p>Early research into HLH demonstrated high levels of serum soluble interleukin 2 receptor (sIL-2R) in affected children. Additionally, levels correlated well with disease activity. (2786434) Since the discovery of sIL-2R, many other cytokines have been implicated in the pathophysiology of the disease, including interferon-gamma (INF-y), tumor necrosis factor (TNF), and IL-2. Limited success has been demonstrated in experiential studies of their related inhibitor antibodies.<xref ref-type="bibr" rid="article-24579.r15">[15]</xref><xref ref-type="bibr" rid="article-24579.r16">[16]</xref></p>
      </sec>
      <sec id="article-24579.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Suspected cases of HLH typically undergo a biopsy of either lymph nodes, bone marrow (BM), or spleen. The historical histopathologic finding is hemophagocytosis, in which macrophages are captured engulfing bone marrow cells. Although pathognomonic, this finding is not actually required for diagnosis. In fact, in patients who otherwise meet diagnostic criteria, pathologic review demonstrates hemophagocytosis present in only 67% of pediatric and 85% of adult cases.<xref ref-type="bibr" rid="article-24579.r7">[7]</xref><xref ref-type="bibr" rid="article-24579.r9">[9]</xref></p>
      </sec>
      <sec id="article-24579.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Given the large clinical overlap between HLH and other systemic inflammatory conditions (severe infection, malignancy, and autoimmune disease), presenting symptoms are often non-specific signs of inflammation such as fever, malaise, and fatigue. Further blurring the distinction between HLH and other multi-organ inflammatory diseases is the fact that such disease processes often serve as the trigger for developing HLH. While children can have spontaneous HLH driven by genetic mutations, they can also develop HLH as the result of an antigenic stimulus or trigger, much in the same way it typically presents in adults. The most common trigger in children with primary HLH is an infection, particularly herpesvirus family infections, and even more specifically, Epstein Barr virus.<xref ref-type="bibr" rid="article-24579.r17">[17]</xref> In adults, the most common trigger is malignancy, accounting for about 45% of adult cases.<xref ref-type="bibr" rid="article-24579.r6">[6]</xref> Because of a relic of history rather than distinct pathophysiology, HLH associated with autoimmune diseases continues to be referred to as macrophage activation syndrome (MAS).&#x000a0;</p>
        <p>The physical exam is similarly protean. Many exam findings can be anticipated by remembering that HLH is a disease of hyper-reactive immune cells with particular attention paid to the reticuloendothelial system. To varying degrees, patients can present with cytopenias with associated bleeding, infection, or stressors related to extreme anemia (myocardial infarction, stroke, syncope) and with hepatosplenomegaly and/or diffuse adenopathy. Additionally, the severe systemic inflammation can present as altered mental status (including life-threatening meningoencephalitis), adult respiratory distress syndrome, acute liver failure, and acute renal failure.<xref ref-type="bibr" rid="article-24579.r1">[1]</xref></p>
      </sec>
      <sec id="article-24579.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>HLH has had two major shifts in classification in its lifetime. The first major classification system was defined in the seminal trial known as HLH-94 (representing the year participants began enrolling), and the more recent definition is referred to as HLH-2004 (again representing the year participants were enrolled in the most recent therapeutic trial). In the last 5 years, attempts to redefine the diagnostic criteria have occurred but are not as validated as either of their predecessors. The original HLH-94 criteria were the following: 5 out of 5 of the criteria must be met to establish a diagnosis.<xref ref-type="bibr" rid="article-24579.r18">[18]</xref></p>
        <p>
<list list-type="bullet"><list-item><p>Fever&#x000a0;</p></list-item><list-item><p>Cytopenias (at a minimal two lineages)</p></list-item><list-item><p>Splenomegaly&#x000a0;</p></list-item><list-item><p>Hypertriglyceridemia +/- hypofibrinogenemia&#x000a0;</p></list-item><list-item><p>Biopsy-proven hemophagocytosis&#x000a0;</p></list-item></list>
</p>
        <p>In the HLH-2004 criteria, 3 further laboratory findings were added to the list. Diagnosis is established by the presence of at least 5 out of the now combined 8 total criteria.<xref ref-type="bibr" rid="article-24579.r19">[19]</xref></p>
        <p>
<list list-type="bullet"><list-item><p>Ferritin greater than 500 ng/ml</p></list-item><list-item><p>Low or absent NK-cell activity</p></list-item><list-item><p>Elevated sIL2Ra levels greater than or equal to 2400 U/ml</p></list-item></list>
</p>
        <p>Notably, per the HLH-2004 criteria, a diagnosis no longer requires the presence of biopsy-proven hemophagocytosis.</p>
      </sec>
      <sec id="article-24579.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The mainstay of treatment focuses on immunosuppression and cytotoxic therapy. Both of these are obviously contraindicated in patients with severe infection and underline the importance of arriving at a clear diagnosis prior to initiation. The landmark HLH-94 protocol was first developed and tested in an international collaborative study that enrolled and gathered data from 113 children.<xref ref-type="bibr" rid="article-24579.r18">[18]</xref> This protocol included a combination of dexamethasone, etoposide, cyclosporine A and intrathecal methotrexate (IT-MTX) in select patients followed by pre-planned bone marrow transplant (BMT). Outcomes of this trial demonstrated a 55% survival rate at 3 years and 5-year survival of 22%, both of which are quite favorable compared to the otherwise invariably rapid death in affected children.<xref ref-type="bibr" rid="article-24579.r3">[3]</xref><xref ref-type="bibr" rid="article-24579.r20">[20]</xref>&#x000a0;</p>
        <p>The HLH-2004 protocol enrolled patients with both primary and secondary HLH and changed the previous protocol slightly by adding cyclosporine to the initial therapy cocktail as well as adding intrathecal steroids to IT-MTX for those with underlying neurologic dysfunction. Study analysis demonstrated no improvement in outcomes with the addition of upfront cyclosporine or intrathecal steroid therapy.<xref ref-type="bibr" rid="article-24579.r19">[19]</xref><xref ref-type="bibr" rid="article-24579.r21">[21]</xref></p>
        <p>In both regimens, conditioning prior to BMT is achieved with reduced-intensity conditioning, such as fludarabine/busulfan.<xref ref-type="bibr" rid="article-24579.r22">[22]</xref></p>
      </sec>
      <sec id="article-24579.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Presenting symptoms are often non-specific or are thought to be accounted for in the context of known sepsis or malignancy. A higher degree of suspicion should be maintained in children who present with symptoms suggestive of Kawasaki disease or toxic shock syndrome. In adults, in which the disease is rarer, presentation is often obscured by another confirmed multi-organ system process such as malignancy, sepsis, or an autoimmune process. A high index of suspicion should be maintained in any patient who presents with multiorgan failure with associated cytopenias, coagulopathy, and failure to improve with standard treatment.</p>
      </sec>
      <sec id="article-24579.s11" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>Clinicians will continue to refine the dosing, duration, and combination of immunosuppression and chemotherapy found in the HLH-2004 protocol. Survival will undoubtedly improve. However, progress will also (and is) being made in the realm of anti-cytokine agents. As mentioned previously, even the earliest of HLH research understood the central role of targeting hypercytokinemia. Various drugs have been developed or repurposed with specific cytokines or cytokine pathway targets, such as ruxolitinib (Janus kinase 1/2 inhibitor) and emapalumab (anti-TNF gamma).</p>
        <p>Ruxolitinib, a medication currently approved for the treatment of myelofibrosis and polycythemia vera, has shown promise in murine models of HLH. Perforin deleted mice were treated with 1 mg/kg for 10 days and demonstrated improved survival, cytopenias, and serum levels of TNF-a and IL-6. Human trials have yet to been undertaken; however, given that it already has FDA approval for other hematologic diseases, such a transition could be expedited.&#x000a0; &#x000a0;</p>
        <p>Phase II pediatric clinical trials have been performed with emapalumab, a novel human monoclonal anti-TNF gamma antibody. A trial of 13 children with refractory or worsening primary HLH, despite treatment, was administered the drug. Response (defined as a complete or partial improvement) occurred in 63% of treated children. 11 of 13 children were alive at 8 weeks.<xref ref-type="bibr" rid="article-24579.r15">[15]</xref><xref ref-type="bibr" rid="article-24579.r16">[16]</xref></p>
      </sec>
      <sec id="article-24579.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Children affected by HLH will invariably die if left untreated, whereas adults can have spontaneous remission without recurrence. Admittedly, it is more difficult to obtain accurate estimates of adult fatality rates since it is often unclear whether deaths are the direct results of HLH or the underlying trigger (infection or malignancy). Retrospective studies have demonstrated a 3-year survival rate of 55% in children who received treatment with HLH-94. In children who survived to undergo BMT, 3-year survival rates reached 62%.<xref ref-type="bibr" rid="article-24579.r3">[3]</xref><xref ref-type="bibr" rid="article-24579.r18">[18]</xref> Despite the fact that adults can have a spontaneous remission of HLH, the overall mortality rate remains quite high at roughly 41%.<xref ref-type="bibr" rid="article-24579.r7">[7]</xref> A recent multi-center case series in the United States demonstrated the poorest survival rates in patients with malignancy-associated HLH. The median time of survival was only 2.8 months (versus 10.7 months in those with non-malignancy-associated disease).<xref ref-type="bibr" rid="article-24579.r4">[4]</xref></p>
      </sec>
      <sec id="article-24579.s13" sec-type="Complications">
        <title>Complications</title>
        <p>It seems redundant to speak of complications in a disease, which, in essence, is nothing but complications. HLH is, by definition, a multi-organ pathology with disease occurring indiscriminately as the result of widespread, dysregulated immune system activity. Lungs can develop acute respiratory distress syndrome, hearts can be affected by myocarditis, and its myriad complications, kidneys can suffer microangiopathies, brains can succumb to fatal meningoencephalitis, livers can acutely fail; in fact, not a single major organ system is spared the devastating effects of this disease. The majority of patients who die from the disease die as a result of hemodynamic collapse.</p>
      </sec>
      <sec id="article-24579.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Hemophagocytic lymphohistiocytosis is a devastating, hyper-inflammatory condition that results in multi-organ failure and death. Primary HLH occurs in children as the result of genetic mutations and secondary HLH in adults after exposure to a strongly immunogenic stimulus such as infection, malignancy, or autoimmune disease. Diagnostic criteria have limited sensitivity/specificity. However, aggressive treatment is required urgently in order to obtain favorable outcomes. Given the myriad of presenting symptoms and multi-organ involvement, patients with HLH are often treated in quaternary hospital ICUs with multiple subspecialties involved in care. A high index of suspicion, as well as good interprofessional communication, is required to establish a diagnosis and initiate appropriate treatment in a timely manner.</p>
      </sec>
      <sec id="article-24579.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24579&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24579">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/lymphohistiocytosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24579">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24579/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24579">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24579.s16">
        <title>References</title>
        <ref id="article-24579.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Samkari</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Berliner</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Hemophagocytic Lymphohistiocytosis.</article-title>
            <source>Annu Rev Pathol</source>
            <year>2018</year>
            <month>Jan</month>
            <day>24</day>
            <volume>13</volume>
            <fpage>27</fpage>
            <page-range>27-49</page-range>
            <pub-id pub-id-type="pmid">28934563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morimoto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nakazawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Hemophagocytic lymphohistiocytosis: Pathogenesis, diagnosis, and management.</article-title>
            <source>Pediatr Int</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>58</volume>
            <issue>9</issue>
            <fpage>817</fpage>
            <page-range>817-25</page-range>
            <pub-id pub-id-type="pmid">27289085</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Janka</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Familial hemophagocytic lymphohistiocytosis.</article-title>
            <source>Eur J Pediatr</source>
            <year>1983</year>
            <season>Jun-Jul</season>
            <volume>140</volume>
            <issue>3</issue>
            <fpage>221</fpage>
            <page-range>221-30</page-range>
            <pub-id pub-id-type="pmid">6354720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schram</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Comstock</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gorovets</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mullally</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bodio</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Arnason</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berliner</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years.</article-title>
            <source>Br J Haematol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>172</volume>
            <issue>3</issue>
            <fpage>412</fpage>
            <page-range>412-9</page-range>
            <pub-id pub-id-type="pmid">26537747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Emile</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Abla</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Fraitag</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Horne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haroche</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Donadieu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Requena-Caballero</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Abdel-Wahab</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Charlotte</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Egeler</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Herrera</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Henter</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Janku</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Merad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Picarsic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rodriguez-Galindo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rollins</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Tazi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vassallo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>LM</given-names>
              </name>
              <collab>Histiocyte Society</collab>
            </person-group>
            <article-title>Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>Jun</month>
            <day>02</day>
            <volume>127</volume>
            <issue>22</issue>
            <fpage>2672</fpage>
            <page-range>2672-81</page-range>
            <pub-id pub-id-type="pmid">26966089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>McClain</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2015</year>
            <volume>2015</volume>
            <fpage>177</fpage>
            <page-range>177-82</page-range>
            <pub-id pub-id-type="pmid">26637718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramos-Casals</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brito-Zer&#x000f3;n</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Guillermo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khamashta</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Adult haemophagocytic syndrome.</article-title>
            <source>Lancet</source>
            <year>2014</year>
            <month>Apr</month>
            <day>26</day>
            <volume>383</volume>
            <issue>9927</issue>
            <fpage>1503</fpage>
            <page-range>1503-1516</page-range>
            <pub-id pub-id-type="pmid">24290661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hadchouel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Prieur</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Griscelli</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection.</article-title>
            <source>J Pediatr</source>
            <year>1985</year>
            <month>Apr</month>
            <volume>106</volume>
            <issue>4</issue>
            <fpage>561</fpage>
            <page-range>561-6</page-range>
            <pub-id pub-id-type="pmid">3981309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meeths</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Horne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sabel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bryceson</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Henter</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Incidence and clinical presentation of primary hemophagocytic lymphohistiocytosis in Sweden.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>62</volume>
            <issue>2</issue>
            <fpage>346</fpage>
            <page-range>346-352</page-range>
            <pub-id pub-id-type="pmid">25382070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niece</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>ZR</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Langevin</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>McClain</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Hemophagocytic lymphohistiocytosis in Texas: observations on ethnicity and race.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>54</volume>
            <issue>3</issue>
            <fpage>424</fpage>
            <page-range>424-8</page-range>
            <pub-id pub-id-type="pmid">19953651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parikh</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Letendre</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wolanskyj</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>89</volume>
            <issue>4</issue>
            <fpage>484</fpage>
            <page-range>484-92</page-range>
            <pub-id pub-id-type="pmid">24581757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henter</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Elinder</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>S&#x000f6;der</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ost</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis.</article-title>
            <source>Acta Paediatr Scand</source>
            <year>1991</year>
            <month>Apr</month>
            <volume>80</volume>
            <issue>4</issue>
            <fpage>428</fpage>
            <page-range>428-35</page-range>
            <pub-id pub-id-type="pmid">2058392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dufourcq-Lagelouse</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jabado</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Le Deist</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>St&#x000e9;phan</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Souillet</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bruin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vilmer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Janka</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Saint Basile</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Linkage of familial hemophagocytic lymphohistiocytosis to 10q21-22 and evidence for heterogeneity.</article-title>
            <source>Am J Hum Genet</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>172</fpage>
            <page-range>172-9</page-range>
            <pub-id pub-id-type="pmid">9915956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Marsh</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kissell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Meller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Villanueva</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Risma</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Filipovich</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH.</article-title>
            <source>Blood</source>
            <year>2011</year>
            <month>Nov</month>
            <day>24</day>
            <volume>118</volume>
            <issue>22</issue>
            <fpage>5794</fpage>
            <page-range>5794-8</page-range>
            <pub-id pub-id-type="pmid">21881043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maschalidi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sepulveda</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Garrigue</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Saint Basile</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>Jul</month>
            <day>07</day>
            <volume>128</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-71</page-range>
            <pub-id pub-id-type="pmid">27222478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daver</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>McClain</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Parikh</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Otrock</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Rojas-Hernandez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Blechacz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Minkov</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>La Ros&#x000e9;e</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kantarjian</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults.</article-title>
            <source>Cancer</source>
            <year>2017</year>
            <month>Sep</month>
            <day>01</day>
            <volume>123</volume>
            <issue>17</issue>
            <fpage>3229</fpage>
            <page-range>3229-3240</page-range>
            <pub-id pub-id-type="pmid">28621800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Greig</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yenamandra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vnencak-Jones</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>The ambiguous boundary between EBV-related hemophagocytic lymphohistiocytosis and systemic EBV-driven T cell lymphoproliferative disorder.</article-title>
            <source>Int J Clin Exp Pathol</source>
            <year>2014</year>
            <volume>7</volume>
            <issue>9</issue>
            <fpage>5738</fpage>
            <page-range>5738-49</page-range>
            <pub-id pub-id-type="pmid">25337215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henter</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Samuelsson-Horne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aric&#x000f2;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Egeler</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Elinder</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Filipovich</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Gadner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Imashuku</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Komp</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ladisch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Janka</surname>
                <given-names>G</given-names>
              </name>
              <collab>Histocyte Society</collab>
            </person-group>
            <article-title>Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation.</article-title>
            <source>Blood</source>
            <year>2002</year>
            <month>Oct</month>
            <day>01</day>
            <volume>100</volume>
            <issue>7</issue>
            <fpage>2367</fpage>
            <page-range>2367-73</page-range>
            <pub-id pub-id-type="pmid">12239144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergsten</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Horne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aric&#x000f3;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Astigarraga</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Egeler</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Filipovich</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Janka</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ladisch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lehmberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>McClain</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Minkov</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nanduri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rosso</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Henter</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Dec</month>
            <day>21</day>
            <volume>130</volume>
            <issue>25</issue>
            <fpage>2728</fpage>
            <page-range>2728-2738</page-range>
            <pub-id pub-id-type="pmid">28935695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aric&#x000f2;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Janka</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Henter</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Blanche</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Elinder</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martinetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rusca</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society.</article-title>
            <source>Leukemia</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>197</fpage>
            <page-range>197-203</page-range>
            <pub-id pub-id-type="pmid">8637226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henter</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Horne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aric&#x000f3;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Egeler</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Filipovich</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Imashuku</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ladisch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McClain</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Winiarski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Janka</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>124</fpage>
            <page-range>124-31</page-range>
            <pub-id pub-id-type="pmid">16937360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24579.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marsh</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Vaughn</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jodele</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Bleesing</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Filipovich</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation.</article-title>
            <source>Blood</source>
            <year>2010</year>
            <month>Dec</month>
            <day>23</day>
            <volume>116</volume>
            <issue>26</issue>
            <fpage>5824</fpage>
            <page-range>5824-31</page-range>
            <pub-id pub-id-type="pmid">20855862</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
